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Cellular/Molecular
A Portable Site: A Binding Element for 17-Estradiol Can Be
Placed on Any Subunit of a Nicotinic 42 Receptor
Xiaochun Jin and Joe Henry Steinbach
Department of Anesthesiology, Washington University School of Medicine, Saint Louis, Missouri 63110
Endogenous steroids can modulate the activity of transmitter-gated channels by directly interacting with the receptor. 17-Estradiol
potentiates activation of neuronal nicotinic 42 receptors by interacting with a 4 aa sequence at the extreme C terminus of the 4
subunit, but it is not known whether potentiation requires that the sequence be placed on a specific subunit (e.g., an 4 subunit that is
involved in forming an acetylcholine-binding site). By using concatemers of subunits and chimeric subunits, we have found that the
C-terminal domain can bemoved from the4 to the2 subunit and still result in potentiation. In addition, the sequence can be placed on
a subunit that contributes to an acetylcholine-binding site or on the structural subunit. The data indicate that this estradiol-binding
element is a discrete sequence and suggest that the effect of 17-estradiol is mediated by actions on single subunits and that the overall
consequences for gating occur because of the summation of independent energetic contributions to overall gating of this receptor.
Introduction
Steroids are endogenous modulators of membrane channel func-
tion. Althoughmany actions of steroids are mediated by alterations
in gene expression initiated by binding to nuclear receptors, steroids
can have rapid and reversible actions on both transmitter-gated and
voltage-gated ion channels (Belelli and Lambert, 2005; Schlichter et
al., 2006). A particularly well studied example is the GABA type A
(GABAA) receptor, for which neurosteroids are among the most
potent and efficacious potentiators (Belelli and Lambert, 2005; Akk
et al., 2007). The fact that steroids can modulate the function of
synaptic receptors provides a rapid link between endocrine and ner-
vous system functions.
The ligand-gated ion channel gene family includes the sub-
units for the vertebrate nicotinic, GABAA, serotonin type 3, and
glycine receptors, and a number of related proteins in inverte-
brates (Brejc et al., 2001; Akabas, 2004; Sine and Engel, 2006).
These receptors form as pentamers of homologous subunits (see
Fig. 1), arranged in a rosette around a central ion channel formed
frommembrane-spanning-helical regions contributed from all
subunits. We are studying the neuronal nicotinic receptor con-
taining4 and2 subunits, to define the sites andmechanisms by
which potentiating agents act on the receptor. The 4 subunit is
expressed inmany brain regions, and the42* receptor is one of
the most common receptor subtypes (Gotti et al., 2007). The
major physiological role of these receptors is to modulate the
release of other neurotransmitters (Dani and Bertrand, 2007).
The endogenous steroid 17-estradiol potentiates the response
of the 42 nicotinic receptor and requires a specific amino
acid sequence at the extreme C terminus of the 4 subunit
(Paradiso et al., 2001; Curtis et al., 2002). We sought to better
define the structural requirements for estradiol potentiation
of this receptor.
The sites at which potentiators interact with receptors in the
ligand-gated ion channel family have been defined for some
drugs. In several cases, the recognition region for the drug is
formed by residues from two subunits at an interface between
subunits (Hsiao et al., 2006; Moroni et al., 2008; Seo et al., 2009).
In others, binding occurs between residues in a single subunit
(Jenkins et al., 2001; Hosie et al., 2006; Li et al., 2006). By using
concatemeric constructs of subunits and mutated subunits, we
examined the effects of placing the 4 C-terminal sequence on
either the 4 or 2 subunit, or on subunits that contribute an
interface to an ACh-binding site or that serve as the structural
subunit (see Fig. 1). Our results show that the C-terminal se-
quence may be placed on either subunit and the subunit may be
in either position in the assembled receptor. These observations
indicate that the C-terminal domain is a discrete and transferable
element underlying 17-estradiol potentiation. Potentiation in-
creases geometrically with the number of C-terminal domains in
the receptor, which suggests that binding of 17-estradiol has an
independent effect on an individual subunit, which adds a con-
stant amount of energy to stabilize the open-channel form of the
receptor.
Materials andMethods
cDNAs and molecular biology. cDNA constructs for human nicotinic re-
ceptor 4 and 2 subunits were kindly provided by J. Lindstrom (Uni-
versity of Pennsylvania, Philadelphia, PA) (4, accession number
NM_000744; 2, accession number NM_000748). The constructs were
transferred to pcDNA3 (Invitrogen).
Two concatemers were constructed, which linked two subunits, as
previously described (Zhou et al., 2003). From the N to C termini, they
are 2-EF(AGS)6-4 (abbreviated /) and 4-EF(AGS)8-2 (/).
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The signal sequence of the second subunit was
deleted. The / concatemer is very similar to
that described previously (Zhou et al., 2003)
[EG(AGS)6], whereas the / concatemer
has a linker two residues longer than the 4-
(AGS)6-2 concatemer described previously
[QEGT(AGS)6TG]. Chimeric subunits were
constructed by overlap extension and smaller
mutations were constructed using QuikChange
(Stratagene). The locations of chimera joining
points are shown in Figure 1.
All constructs were sequenced through the
entire coding region.
Receptor expression and oocyte voltage clamp.
cRNA was synthesized using the mMessage
mMachine T7 kit (Ambion). The concentra-
tion of mRNA was estimated from the OD260
value. When combinations of free subunits
were injected, the ratio of construct with an 4
N terminus to that with a 2 N terminus was
8:1 (mass ratio), unless otherwise specified.
When concatemers were injected with free
subunits, the ratio was 2:1.
Xenopus oocytes were prepared in the labo-
ratory of Dr. C. Zorumski (Washington Uni-
versity, St. Louis, MO) using an approved
protocol. Oocytes were injected with 12–15 ng
of cRNA in a volume of 18–23 nl. Oocytes were
maintained at 18°C for 2–7 d before physiolog-
ical study.
Standard methods were used for two-
electrode voltage clamp of Xenopus oocytes
(Steinbach et al., 2000; Paradiso et al., 2001; Jin
et al., 2009), using an OC-725C voltage clamp
(Warner Instruments). Currents were filtered
at 20 Hz, and then digitized at 50 Hz (Digidata
1200 interface; Molecular Devices) and stored
using pClamp 8.0 (Molecular Devices). Tran-
sients were analyzed with Clampfit (Molecular
Devices). Oocyte recordings were performed in a small chamber that was
continuously perfused with saline. Drug applications were made using a
manually controlled perfusion system. The system was made with glass,
stainless-steel, or Teflon components, to reduce steroid adsorption. The
applications were relatively slow, with bath exchange times of1 s. The
external solution contained the following (in mM): 96 NaCl, 2 KCl, 1.8
BaCl2, 1MgCl2, and 10HEPES, pH 7.3. External Ca
2was replaced with
Ba2, to avoid activation of Ca2 activated channels. We did not use
atropine to block muscarinic receptors, as it potentiates 42 receptors
(Zwart and Vijverberg, 1997). Occasional oocytes showed delayed re-
sponses to ACh; these oocytes were discarded.
The concentration–response relationship for activation by ACh was
characterized by fitting the Hill equation, Y([ACh])  Ymax(1/(1 
(EC50/[ACh])
^nHill)), whereY is the response to a concentration of ACh,
Ymax is the maximal response, EC50 is the concentration producing half-
maximal activation, and nHill is the Hill coefficient. Concentration–re-
sponse data were collected for an individual cell, and data were
normalized to the response to 1 mM ACh. The fit was rejected if the
estimated error in any fit parameter was 60% of the fit value, and all
parameter estimates for that fit were discarded. The relationship was
analyzed for each cell, and then overall mean values were calculated for
oocytes injected with that set of constructs.
Potentiation by 17-estradiol is strongest for low concentrations of
ACh (Paradiso et al., 2001; Curtis et al., 2002). Since the EC50 for activa-
tion by ACh depends on the subunit combinations expressed (see Re-
sults), each oocyte was tested with 1 mM ACh, to estimate the maximal
response. A low concentration of ACh, chosen to be able to evoke20%
of the maximal current, was then applied. After the response to ACh had
reached a stable level, the application was switched to ACh plus 10 M
17-estradiol. The application was switched to bathing solution, fol-
lowed by repeat of the control low concentration. The relative response
in the presence of 17-estradiol was then calculated. 17-Estradiol was
not preapplied, as the onset and offset of potentiation are rapid (Paradiso
et al., 2001). ACh or ACh plus 17-estradiol were applied for 10–20 s,
and applications were separated by 3–4 min, to allow full washout.
The amplitudes of currents expressed by some combinations of con-
structs weremuch larger than for others (supplemental Table 1, available
at www.jneurosci.org as supplemental material). We are exploring pos-
sible reasons for this, but do not have an explanation at present. Experi-
mentally, to accept a value for potentiation by 17-estradiol, the control
response had to be at least 5 nA. For analysis of agonist concentration–
response relationships, themaximal response had to be at least 50 nA. To
avoid problems of clamp control, the maximal response also had to be
30A. For some constructs, the low response amplitude required us to
use a higher than usual concentration of ACh, whichmight have reduced
the estimated potentiation (supplemental Table 2, available at www.
jneurosci.org as supplemental material).
Values are presented as arithmetic mean  SE (number of observa-
tions). Statistical tests were made using Excel (Microsoft) or Systat (Sys-
tat Software). Unless otherwise indicated, statistical tests were two-tailed
t tests with unequal variance.
Receptor extraction and Western blots. Groups of 40–50 oocytes were
injected with mRNA, as described previously. Membrane proteins were
extracted basically as described previously (Carbone et al., 2009). In brief,
oocyteswere suspended in an ice-cold homogenization buffer containing
the following (inmM): 150NaCl, 2 CaCl2, 2%TritonX-100, 20 Tris-HCl,
pH 7.4, supplemented with protease inhibitor mixture (Sigma-Aldrich;
P8465), at a ratio of 5l of buffer per oocyte. Oocytes were homogenized
by passing through a 20 gauge needle seven times and a 27 gauge needle
three times, and then extracted for 30 min on ice. Homogenates were
Figure1. Schematic viewsof the receptor and subunits. The toppanel shows theoverall arrangements inpentamers containing
concatemers. Subunits are arranged around the ion channel (dotted circle). ACh-binding sites are indicated by the diamonds
between an4 subunit (contributing the positive or side of the interface) and a2 subunit. Four subunits contribute to the
agonist-binding sites,whereas the fifth occupies a “structural” position. The concatemers are indicatedwith linkers connecting the
C terminus (denoted by a circle with C) to the N terminus, as shown by the arrowheads. The fainter diamonds on the free subunit
assembledwith the/ concatemer indicate that the site is located on opposite sides, depending on the nature of theN-terminal
sequence of the free subunit (note that the structural subunit in this combination is contributed fromone of the concatemers). The
bottompanel shows the constructs used. The top pair shows sequence for the chimeras-M3- and-M3-. The line above the
sequences shows the position of the C-terminal end of the M3 region. The joining point is indicated by the arrow; the sequences
were swapped for all positions including and following the indicated residue. The bottompair shows theM43 C andWLAGMI
constructs. The line shows thepositionof thepredictedM4 region. Thebold letters indicate aminoacid residues in thepredictedM4
region that differ between4 and2.
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centrifuged twice at 1000 g for 5min at 4°C to remove the yolk, and the
supernatantswere then recentrifuged at 10,000 g for 10min at 4°C. The
cleared supernatants were collected and diluted 50:50 in 2 Laemmli
sample buffer (Bio-Rad) supplemented to 100 mM DTT. Samples were
placed at room temperature for 30min, and then aliquots were loaded on
precast 7.5% gels (Bio-Rad). After electrophoresis, proteins were trans-
ferred to PVDF (polyvinylidene difluoride) membranes (Millipore).
Membranes were blocked for 1 h at room temperature with 100%Odys-
sey block solution (LI-COR Biosciences), followed by overnight incuba-
tion at 4°C in a solution of 50% Odyssey block solution/50% PBS (137
mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, pH 7.3)
containing 0.4% Tween 20 (Sigma-Aldrich) with primary antibody.
Polyclonal rabbit antibody to 4 subunit (sc5591; Santa Cruz Biotech-
nology) and goat antibody to 2 (sc1449; Santa Cruz Biotechnology)
were used at 1:300. Membranes were washed four times with PBS con-
taining 0.2% Tween 20, and then incubated with secondary antibody in
the dark for 45 min at room temperature. Goat anti-rabbit and donkey
anti-goat labeled with IR dye 680 (LI-COR Biosciences) were used at
dilutions between 1:5000 and 1:20,000. Membranes were washed five
times with PBS plus 0.2% Tween 20 and scanned on an Odyssey Infrared
Imaging System (LI-COR Biosciences).
Drugs. 17-Estradiol (CAS 50-28-2), acetylcholine chloride (ACh) (CAS
60-31-1), and 19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17)-(9CI)
(17-vinylestradiol) (CAS 57-63-6) were purchased from Sigma-Aldrich.
5-Iodo-3-(2(S)-azetidinylmethoxy)pyridine (5I A85380) (CAS 213764-
92-2) was purchased from Tocris. Steroids were prepared as a 20 mM stock
solution inDMSOanddiluted into external solution on the day of an exper-
iment. AChwas prepared as a 1 M stock solution in bath solution and stored
frozen at20°C. 5I A85380 was prepared as a 50M stock solution in bath
solution and stored frozen at20°C. Working solutions were prepared on
the day of experiments.
Characterization of receptors containing concatemers. We wanted to
control the subunit stoichiometry and subunit position in 42 recep-
tors. To accomplish this, we generated two concatemers, following the
approach described by Zhou et al. (2003), one with the 2 subunit at the
N terminus (abbreviated/) and the otherwith4 (/).We expressed
each concatemer in oocytes, both alone and with free 4 or 2 subunits
(Table 1). We confirmed that concatemers expressed alone produce
functional receptors. However, in the presence of a free subunit, the
resulting receptors appear to reflect the properties of receptors composed
of two concatemers plus a single free subunit (Zhou et al., 2003). Expres-
sion with a free 2 subunit results in a population of receptors with a
small EC50 for activation by ACh, whereas free 4 subunit results in
receptors with a large EC50 (Table 1). The values are similar to those for
free subunits expressed at a low4:2 ratio or a high4:2 ratio, respec-
tively (Table 1) (Zwart and Vijverberg, 1998; Moroni et al., 2006). We
also examined gating by the subtype-selective agonist, 5I A85380. This
agonist has different EC50 values for activation of the two forms:10 nM
for (4)2(3)3 versus18,000 nM for (4)3(3)2 (Zwart et al., 2006). In
addition, the maximal response is actually greater than the maximal
response to ACh for the (4)2(3)3 receptor (Zwart et al., 2006). We
determined the response to 1 M 5I A85380 relative to the response to 1
mM ACh. 5I A85380 activates receptors incorporating free 2 (resulting
in receptors containing three copies of 2) much more strongly than
those with free 4, as expected from studies with free subunits (Table 1).
Overall, these results indicate that the concatemers assemble with free
subunits to generate pentameric receptors with properties appropriate
for the stoichiometry predicted for incorporation of the free subunit, as
reported previously (Zhou et al., 2003).
The fact that we produce surface receptors by combining subunit con-
catemerswithmutated free subunits raises the possibility that some com-
binations assembled inappropriately (for example excluding the free
subunit). We cannot rule this out, but for most combinations we deter-
mined the EC50 for activation by ACh and the relative gating by 1 M 5I
A85380 compared with 1 mM ACh (supplemental Table 1, available at
www.jneurosci.org as supplemental material). As mentioned previously,
these values provide an indication of the numbers of 4 and 2 subunits
present in the functional receptors. Our unpublished data indicate that
the N-terminal extracellular domain is the primary determinant for both
of these parameters; that is, when three 2 extracellular domains are
present in the receptor, the EC50 will be small (10 M or less) and the
relative response to 5I A85380 will be large (1.0 or greater), in contrast to
the case when only two are present. Figure 2 shows a plot of relative
response against log(EC50) and shows that the data fall into two distinct
groups. The groups indicate that the functional receptors contain the
number of 2 extracellular domains expected if the free subunits incor-
porated into the pentameric receptor. As shown in Results, we also found
that a single free 4 subunit confers potentiation by 17-estradiol, indi-
cating that it also incorporates into the assembled pentameric receptors.
Accordingly, the constructs we have used behave in the expected way,
and the majority of pentameric receptors include both concatemers and
free subunits. We cannot rule out the possibility that there is a small
fraction of receptors that did not incorporate free subunits.
We note that our data indicate that both the/ and/ concatemers
when expressed without free subunits behave as though receptors in-
clude three4 subunits. This differs from the results obtained by Zhou et
al. (2003), who observed that the / receptor had a small EC50 for ACh.
We also confirmed by Western blot that concatemers do not signifi-
cantly degrade into individual subunits in the oocytes (Fig. 3) (Zhou et
al., 2003; Carbone et al., 2009).
We sought to incorporate the free subunit selectively into a defined
position in the pentamer, either a position in which it contributed to an
agonist-binding site or one in which it did not. Accordingly, we con-
firmed the arrangements proposed by Zhou et al. (2003) for subunits in
receptors formed by a concatemer plus a free subunit (Fig. 1). To do this,
we used a mutation in the E-loop of the agonist-binding site contributed
by the 2 subunit, which we had previously shown to affect activation by
5I A85380 (2F119Q) (Hamouda et al., 2009). We expressed 2F119Q
with each concatemer and determined activation by 5I A85380 and ACh.
As shown in Figure 4, when 2F119Q is expressed with the / concate-
mer, activation is indistinguishable fromwhenwild-type2 is expressed.
In contrast, when expressed with the / concatemer, activation by 5I
A85380 is shifted toward higher concentrations and lower efficacy. The
EC50 for activation by ACh is not affected [5  1 M (five cells) for
/&2F119Q and 9  3 M (seven cells) for /&2F119Q], as ex-
pected from results with free subunits (Hamouda et al., 2009). These
Table 1. Basic characterization of receptors containing concatemers
ACh EC50 (M) 5I A85380 response 10M 17-Estradiol
Combination Mean SE N Mean SE N Mean SE N p
4&2 1:8 6.6 1.4 14 1.44 0.06 11 2.56 0.12 7 0.000
4&2 8:1 131 11 25 0.19 0.03 9 2.96 0.30 12 0.000
/ 105 23 18 0.16 0.01 16 0.85 0.06 5 0.047
/ 121 16 48 0.44 0.04 62 3.17 0.25 6 0.000
/&4 87 8 33 0.14 0.01 29 1.47 0.07 27 0.000
/&4 140 14 43 0.17 0.01 46 3.77 0.20 11 0.000
/&2 2.9 0.6 12 1.84 0.07 16 1.04 0.06 11 0.560
/&2 4.4 0.8 29 1.59 0.07 34 3.73 0.32 7 0.000
The first columnnames the constructs injected. Thenext three columns give data on activation byACh in terms of the EC50 value providedby a fit of theHill equation. The three columnsheaded 	5I A85380 response	give data on the response
to 1M 5I A85380 normalized to the response to 1mM ACh, for that cell. The columns headed 	10M 17-Estradiol	 give data for the potentiation by 10M 17-estradiol of a response to a low concentration of ACh; the column headed
p gives the probability that the potentiation ratio differs significantly from 1 (no effect), by two-tailed t test.
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observations confirm the proposed arrangement (Zhou et al., 2003), that
the free subunit contributes to an agonist-binding interface when ex-
pressed with the / concatemer but not the / concatemer (Fig. 1).
Results
Previous studies of the ability of 17-estradiol to potentiate the
nicotinic 42 receptor have found that potentiation requires a
specific sequence at the C-terminal of the4 subunit (Paradiso et
al., 2001; Curtis et al., 2002). Mutagenesis of the sequence (Par-
adiso et al., 2001) demonstrated that not only a specific set of
residues is required but that the position of the sequence with
respect to the final (fourth) transmembrane helix is critical: in-
sertion or deletion of a single residue tomove the domain further
from or closer to the external end of the helix abolishes potenti-
ation. Finally, addition of even a single residue at the end of the
domain also abolishes potentiation by 17-estradiol.
In light of these observations, our initial hypothesis was that
potentiation requires that the C-terminal domainmust be placed
on an 4 subunit and, additionally, that the 4 subunit must
participate in ACh binding. To test this hypothesis, we need to
control the number and position of mutated subunits in the as-
sembled receptor. The use of concatemeric constructs of subunits
(Zhou et al., 2003; Carbone et al., 2009) allows this control. We
generated two concatemers, one with the 4 subunit at the N
terminus (referred to as/) and the other with the2 subunit at
the N terminus (/) using the approach developed by Zhou et
al. (2003) (see Materials and Methods). Our characterization of
the concatemers demonstrates that the functional receptors gen-
erated when a concatemer is expressed with a free subunit show
the properties of a receptor that includes two copies of the con-
catemer with one copy of the free subunit (see Materials and
Methods). Furthermore, the use of a point mutant in the 2
subunit confirmed the subunit positions defined by Zhou et al.
(2003) (seeMaterials andMethods) (Fig. 1).When a free subunit
is expressedwith the/ concatemer, it will occupy the structural
(non-agonist-binding) position in the receptor, whereas with the
/ subunit it will occupy an agonist-binding position (Fig. 1).
The concentration of ACh used to elicit responses and to test
potentiation was relatively low (0.1 to 1 M) and, for almost all
constructs, elicited20% of the response to 1 mM ACh (supple-
mental Table 2, available at www.jneurosci.org as supplemental
material). We used 10M 17-estradiol as the standard test con-
centration of potentiator.
Sample traces of potentiation for the most important combi-
nations of constructs are shown in Figure 5. The data for the
potentiation ratios for all combinations studied are shown in
supplemental Table 2 (available at www.jneurosci.org as supple-
mental material).
Figure 2. The free subunit participates in the assembled receptor, as indicated by responses
to agonists. The relative response to 5I A85380 is plotted against the EC50 for ACh; when the
receptor contains three2 subunit N-terminal domains, the relative response is large, and the
EC50 is small (free subunitswith an4:2 ratio of 1:8; black square). Conversely, when two2
subunits are present, the relative response is small and the EC50 is large (free subunits with an
4:2 ratio of 8:1; black triangle). The hollow squares show data for combinations in which it
is predicted that three2 subunit N-terminal domainswould be present if receptors contained
two copies of a concatemer anda single copyof the free subunit,whereas hollow triangles show
data for receptors with two predicted2 N-terminal domains. The black circles show data for
the two concatemers expressedwithout a free subunit. Themeans of valueswith two predicted
2 N termini are 5I A85380 relative response of 0.30 0.04 (N 14 combinations) and
EC50 97 9M, whereas with three predicted 2 N termini the means are 1.47 0.08
(N 9 combinations) and 6.2 2.7M. The means differ at p 106 for each parameter.
Data show mean  SE, for 27 combinations of constructs (data from 3 or more oocytes),
including concatemers alone and combinations of free subunits. The full data set is shown in
supplemental Table 1 (available at www.jneurosci.org as supplemental material).
Figure 3. Concatemers do not appear to be significantly degraded. The panels show two
blots of the same transfer of proteins extracted from four batches of oocytes, injected with
different constructs on the sameday. InA, the transferwas probedwith antibody to4 (H-133;
sc5591). InB, the transfer was stripped and reprobedwith antibody to2 (C-20; sc1449). Note
that there appears to be some breakdown of4 in extracts from oocytes injectedwith4&2
subunits. However, it does not appear that concatemers break down to a significant extent. For
each preparation, 50 oocytes were used. Approximately 230 g (20% of preparation) of
protein loaded in lanes 2, 3, and 4, and50g in lane 1 (5% of prep). These images are
representative of eight gels from threeprotein preparations. Images are shown ingrayscale and
reversed intensity scale to allow visualization of minor bands.
A B
Figure 4. Activation by 5I A85380 indicates positions of subunits in receptors containing
concatemers.A shows the relativegating (normalized to the response to1mMACh for the tested
cell) for/ concatemers assembledwithwild-type2 (black triangles and solid black line) or
with2F119Q (hollow triangles and dashed line). The parameters for a Hill equation fit to the
data are as follows: EC50, 8 1 nM; maximal response, 1.44 0.07-fold for 2; and EC50,
127  14 nM; maximal response, 1.13  0.11-fold for 2F119Q (the Hill coefficient was
constrained to 1 for fits). The hollow circles show responses of the 4/2 concatemer ex-
pressed alone. B shows comparable data for the / concatemer expressed with 2 or 2
F119Q. The parameters for a Hill equation fit to the data are as follows: EC50, 29 12 nM;
maximal response, 1.44 0.10-fold for2; and EC50, 16 1 nM; maximal response, 1.29
0.04-fold for2F119Q (theHill coefficientwas constrained to1 for fits). Fit parameters anddata
points are mean 1 SE, for data from six cells.
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17-Estradiol potentiation is conferred whether the 4
subunit participates in ACh binding or serves as the
structural subunit
We confirmed that the / concatemer, expressed alone, is not
potentiated by 10M 17-estradiol, whereas the/ concatemer
is (Zhou et al., 2003) (Table 1). This indicates that potentiation
requires one or more intact, untethered C-terminal domains on
the 4 subunit. When the / concatemer is expressed with free
2 subunit (abbreviated as /&2), potentiation is also absent,
whereas coexpression of the/ concatemerwith free4 subunit
results in potentiation (Fig. 5, Table 1). This observation indi-
cates that a single intact 4 C terminus is sufficient to allow some
potentiation. Overall, comparing /&4 to 4&2 (8:1) indi-
cates that potentiation for the/&4 receptor is greater than for
receptor composed of free subunits ( p  0.04) as well as for
/&2 compared with 4&2 (1:8) receptors ( p 0.01).
Coexpression of the / concatemer with free 4 subunit
results in a receptor in which the 4 subunit that has an intact C
terminus also participates in forming an ACh-binding interface
(Fig. 1). To determine whether this is required, we tested addi-
tional constructs.
The first manipulation tested the effects of a mutation of the
4 subunit C terminus. Potentiation by 17-estradiol is lost
when the 4 C-terminal WLAGMI is mutated to WLAAC (ab-
breviated WLAAC) (Paradiso et al., 2001). Expression of
WLAAC with / removes potentiation (Fig. 6), as expected.
We thenmutated the untethered C terminus of the 4 subunit in
the / concatemer (/WLAAC). When the /WLAAC con-
catemer is expressed with free4, potentiation is present, but not
when it is expressed with free 2 (Fig. 6). These observations
indicate that potentiation can occur
whether the 4 subunit contributes to an
agonist-binding interface (when expressed
with the/ concatemer) or acts as a struc-
tural subunit (when expressed with the
/WLAAC concatemer). They also con-
firm that only a single subunit need con-
tain the WLAGMI sequence to underlie
potentiation.
Incorporation of a single 4 subunit
with anuntetheredWLAGMIdomain con-
fers estradiol potentiation on the recep-
tor. We compared two combinations of
constructs. In the case of /&4 to
/&4WLAAC, the difference in po-
tentiation ratio is significant at p  5 
108 (t test). For /WLAAC&4 to
/WLAAC&4WLAAC, the difference is
significant at p 8 107. These observa-
tions support the conclusion that free 4
subunits incorporate efficiently when ex-
pressed with either concatemer.
A 17-estradiol binding element can be
placed on either4 or2 subunits
We then examined the question of whether
potentiation required the rest of the4 sub-
unit or was based on the C-terminal region
alone. The initial constructs were chime-
ric subunits between 4 and 2 subunits,
with a join just after the end of the third
membrane spanning region (abbrevi-
ated -M3- and -M3-) (Fig. 1). In
these chimeras, the N-terminal extracellular domain and the
first three transmembrane domains are from one subunit,
whereas the large cytoplasmic loop, the fourth transmem-
brane domain and the C-terminal tail are transferred. As ex-
pected, replacing the C-terminal domain of the 4 subunit
with sequence from 2 removes potentiation when expressed
with the / concatemer (Figs. 5, 6; supplemental Table 2,
available at www.jneurosci.org as supplemental material).
More surprisingly, transferring the 4 sequence to 2 confers
potentiation (Fig. 6). This observation indicates that the
N-terminal extracellular domain and the first three trans-
membrane domains are not sufficient for potentiation. Poten-
tiation is transferred whether the free subunit occupies the
structural position or contributes to an agonist-binding inter-
face (Fig. 6).
We constructed two additional chimeric subunits. These in-
volved transferring the fourth transmembrane segment plus the
WLAGMI sequence (M43C) from the 4 subunit to the 2
subunit, or only the WLAGMI sequence (WLAGMI). The 6 aa
sequence was transferred, as previous work has indicated that the
length of the C-terminal sequence is critical for potentiation
(Paradiso et al., 2001). Both of these chimeras allow potentiation
when expressed with the /WLAAC or the / concatemer
(Fig. 6). These data indicate that the terminal residues are critical
for potentiation. However, the amount of potentiation is signif-
icantly greater for the M43C construct than for 4 or
WLAGMI when expressed with either the / or /WLAAC
concatemers, and for -M3- expressed with / (one-way
ANOVA for each concatemer separately, with Bonferroni’s cor-
Figure 5. The responses to ACh and ACh plus 10M 17-estradiol are shown for oocytes injected with selected combinations
of subunits. The times of drug application are indicated by the horizontal bars above the traces: the top bar shows the application
of a low concentration of ACh alone, whereas the bottom bar shows the application of ACh plus 10M 17-estradiol. The left
column shows responses from oocytes injectedwith the/ concatemer and different free subunits; in this combination the free
subunit contributes to an ACh-binding site. Note that a single copy of wild-type 4 produces a receptor that is potentiated by
17-estradiol, whereas 2 does not, and swapping the portions of the subunit from the end of M3 to the C terminus transfers
potentiation or lack thereof. Calibration (top panel): 10 s (all panels); 260 nA (/&4), 34 nA (/&2), 29 nA (/&-M3-
), 14 nA (/&-M3-). The right column shows responses from oocytes injected with the /WLAAC concatemer and
different free subunits; in this combination, the free subunit occupies the structural position. Note that a single copy of wild-type
4 produces a receptor that is potentiated by 17-estradiol, whereas2 does not, and swapping the last six residues from4 to
2 transfers potentiation. Calibration (top panel): 10 s (all panels); 1800 nA (/WLAAC&4), 68 nA (/WLAAC&2), 11 nA
(/WLAAC&WLAGMI).
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rection). We note, however, that mutation of WLAGMI to
WLAAC in the intact 4 subunit removes potentiation.
We noted that transferring the WLAGMI sequence to 2 re-
sulted in the C-terminal sequence QPWLAGMI. Previous work
(Paradiso et al., 2001) showed that mutation of both prolines in
4 (PPWLAGMI to AAWLAGMI) abolishes potentiation, so we
mutated the glutamine to proline in 2WLAGMI to produce
2PPWLAGMI. Expression of the resulting construct did not
increase potentiation to the same level as seen with the M43C
mutation (Fig. 6).
Overall, these data indicate two points. First, transfer of the
TM4 region plus the tail produces more potentiation than the
simple transfer of the C-terminal tail. Second, the cytoplasmic
loop of the 4 subunit (from the end of TM3 to the start of TM4)
appears to diminish potentiation compared with the amount
produced when only the TM4 to the C terminus is transferred.
The observation that the WLAGMI domain can be moved
from one subunit to another is quite surprising. Our data suggest
that potentiation does not differ greatly depending on whether
the tail is placed on the 4 or 2 subunit. Pooling the data for
receptors containing single copies of WLAGMI, the mean values
for potentiation are, for2N-terminal constructs, 2.3 0.3-fold
(mean  SE; N  8 combinations of constructs), and, for 4
N-terminal constructs, 1.6 0.1-fold (N 2) ( p 0.03). Sim-
ilarly, it does not appear to matter whether the domain is placed
on the structural subunit (mean potentiation, 2.4  0.5-fold;
four combinations) or on a subunit contributing to an ACh-
binding interface (2.0  0.2-fold; six combinations) ( p  0.8).
These conclusions are tentative, given the relatively small number
of cases examined and the possibility for confounding factors.
Our observations indicate that potentiation can occur when
only a single copy of a free WLAGMI domain is incorporated in
the assembled receptor. Furthermore, the WLAGMI sequence
can be placed on the 4 or 2 subunit, and the subunit can
participate in forming an agonist-binding interface or serve as the
fifth, structural, subunit. There are trends suggesting that poten-
tiation may be larger when the receptor includes concatemers,
and may be larger when the domain is present on a 2 subunit
rather than an 4 subunit. There is also an indication that some
portions of the 4 cytoplasmic loop (between the third and
fourth transmembrane regions) might reduce potentiation,
whereas some portions of the fourth transmembrane regionmay
enhance potentiation. These observations suggest the existence of
additional factors that influence the extent of potentiation, which
will have to be examined in additional experiments.
Relationship between copy number and potentiation
There is a significant increase in potentiation as the total number
of WLAGMI C-terminal domains increases in a pentameric
receptor. The average value for potentiation by 10 M 17-
estradiol increases from 0.97  0.02 (0 domains, 10 combina-
tions tested) to 2.2 0.2 (1 domain, 10), 2.4 0.4 (2 domains, 5),
3.3 0.2 (3 domains, 4), to 3.7 0.3 (5 domains, 3). Regression
of potentiation on the number of untethered domains gives a
slope of 0.6 (p 107 that the slope is zero).
Our data were obtained using a constant concentration of
17-estradiol, and it is possible that changes in both potency and
efficacy occurred for some of the constructs. Accordingly, we de-
termined the concentration–effect relationship for 17-estradiol
for combinations of subunits that have one to five untethered
WLAGMI sequences. Two combinations of constructs were
tested for each number of untethered WLAGMI. The combina-
tionswere chosen to keep the number of2N termini constant at
2 in the assembled pentamers, but some combinations were
formed without the use of concatemers and the domains were
placed on agonist-binding or structural subunits. The concentra-
tion–potentiation data are shown in Figure 7, and the fit param-
eters are given in Table 2.
The fit maximal potentiation is plotted against the number of
untethered WLAGMI domains in Figure 8. There is a clear
increase in maximal potentiation with increasing untethered
WLAGMI. The increase is greater than linear, with each added
untethered WLAGMI increasing the potentiation by 1.6-fold.
The geometric fit shown in Figure 8 is a better description than
the linear fit, although there is an indication that the increase
from three to five domains is not as great as might be expected.
This could result from several possible factors. Some are techni-
cal, for example as a result of particular constructs providing a
somewhat greater or lesser amount of potentiation than others.
However, it is also possible that there is a “ceiling” on the amount
of potentiation. This could arise because there is a maximal po-
tentiation possible by the mechanism used by estradiol (so that
five domains occupied by 17-estradiol would not be 1.62 as
efficacious as three), or it could be that there is some interaction
among bound estradiols so that there is amaximal possible num-
ber that can bind. Additional experiments will be necessary to
distinguish among these possibilities.
Our test concentration of 17-estradiol (10 M) is not a sat-
urating concentration for any of these constructs. Accordingly,
the potentiation ratios we calculate for the screening data may
reflect both efficacy and potency. However, the qualitative con-
Figure6. Transferring the2C terminus to4 removes potentiationby 17-estradiol, and
transferring the4 C-terminal domain to2 confers potentiation. Combinations of constructs
were chosen in which there are no free WLAGMI domains except in the added free subunit.
When expressed with the / concatemer, the free subunit occupies a position in which it
contributes to an ACh-binding site, whereaswhen expressedwith the/WLAAC concatemer
it occupies the structural position (Fig. 1). The figure shows the mean response ratio in the
presence of 10 M 17-estradiol (1 SE). The labels for the bar show the combination of
constructs expressed and the number in parentheses shows the number of free C-terminal
domains in the postulated pentamer. The significance levels are shown on the right for the
probability that the ratio differs from 1 (no effect, shown by the heavy dashed line): ns, p
0.05; *p  0.05; **p  0.01; ***p  0.001. The numbers of oocytes tested is shown in
parentheses after the significance level. The two dashed lines indicate a response ratio of 1 (no
effect; heavy line) or themean level for freewild-type4 expressedwith that concatemer (thin
line). Full data are shown in supplemental Table 2 (available at www.jneurosci.org as supple-
mental material).
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clusions about placement of the untethered WLAGMI domain
are clear.
Potentiation by 17-vinylestradiol
The steroid analog 17-vinylestradiol also potentiates the 42
receptor. Previous work (Paradiso et al., 2001) has found that
potentiation by this analog does not require the final four resi-
dues of the 4 C terminus, although potentiation is larger when
the AGMI sequence is present. To remove potentiation, it is neces-
sary to alsomutate a tryptophan residue just preceding the terminal
sequence (i.e., to convert WLAGMI to LLAAC). Mutation only of
the tryptophan (to LLAGMI) does not reduce potentiation by either
17-vinylestradiol or 17-estradiol, emphasizing the overall greater
importance of the AGMI sequence for potentiation (Paradiso et al.,
2001). Assuming that the transduction mechanism is the same for
potentiation by 17-vinylestradiol or 17-estradiol, these observa-
tions indicate that neither the AGMI sequence nor the critical tryp-
tophan is required for the transduction of molecular recognition
into functional potentiation. Accordingly, this steroid analog pro-
vides a control to indicate that the transduction mechanism
for potentiation is preserved when potentiation by 17-
estradiol is removed.
We tested a number of the combinations described above (a
total of 17) (supplemental Table 3, available at www.jneurosci.
org as supplemental material) and found that 17-vinylestradiol
potentiates all of them. For the five cases in which there are no
untethered AGMI and two or three critical tryptophans, the
mean potentiation by 17-vinylestradiol is 2.3  0.6, whereas
17-estradiol on average has no effect (0.94  0.04). Overall,
potentiation increases with increasing numbers of critical tryp-
tophans (associated with increasing numbers of untethered
AGMIs) from 3.1 1.5 (N 2) for two tryptophans, to 6.1 1.7
A
B
Figure 7. An increased number of free WLAGMI domains results in increased maximal po-
tentiation by 17-estradiol. Potentiation is plotted against the concentration of 17-estradiol
for eight combinations of constructs. A shows data for receptors containing one (/
LAAC&WLAGMI and /&4; solid lines show fits) or three (4&2 8:1 and
/&M43 C; dash-dot lines) free WLAGMI domains. B shows data for two
(WLAAC&WLAGMI 8:1 and /&-M3-; dash-dot-dot lines) or five (4&2WLAGMI
8:1 and 4&M43 C 8:1; dashed lines) domains. The number of free WLAGMI domains in
each combination is shown in parentheses. The lines show fits of the equation r  1 
Rmax([Est]/(EC50 [Est]), where R is the response ratio, Rmax is themaximal ratio, [Est] is
the concentration of 17-estradiol, and EC50 is the concentration producing a half-maximal
effect. (The Hill coefficientwas constrained to 1.) The fit values are shown in Table 2. The points
show the mean SE, and the dashed line at a ratio of 1 shows no effect.
Table 2. Concentration dependence for potentiation by 17-estradiol
Combination Rmax 1 EC50
Constructs No. free WLAGMI Mean SE Mean SE N
/&4 1 1.54 0.1 23.3 5.7 6
/WLAAC&4 1 2.04 0.1 9.4 3.1 4
/&-M3- 2 2.96 0.2 4.5 0.6 9
WLAAC&WLAGMI 8:1 2 2.97 0.2 21.1 3.5 7
4&2 8:1 3 5.00 1.0 8.0 1.1 4
/&4 3 5.81 0.3 6.3 1.0 7
4&WLAGMI 8:1 5 7.19 0.6 19.0 3.4 4
4&M43 C 8:1 5 13.44 1.0 39.2 13.6 4
The first column names the constructs injected. The next column lists the number of free C-terminal WLAGMI
sequences predicted to be in the assembled receptor. The next columns give the parameters obtained from fitting
the concentration– effect relationships (Fig. 7)with the equation R 1 Rmax(
Est/(EC50
Est), where R
is the response ratio, Rmax is the maximal ratio, 
Est is the concentration of 17-estradiol, and EC50 is the
concentration producing a half-maximal effect. Themean values shown are themeans of fits to data fromN oocytes
injectedwith that combination. An ANOVAwith Bonferroni’s correction indicates that the value for EC50 is larger for
4&M43 C than for all other combinations except for/&,WLAAC&WLAGMI, and4&WLAGMI. EC50
for/&4 is larger than for/&-M3-, but no other differences are significant. For values of Rmax , the value
for4&M43 C is larger than that for all other combinations. Otherwise, values for combinationswith one or two
free WLAGMI do not differ significantly from each other, nor do values for three or five free WLAGMI. All values for
combinations with one or two free WLAGMI were significantly less than all combinations with three or five, except
forWLAAC&WLAGMI 8:1 whose value for Rmax does not differ significantly from that for4&2 8:1.
Figure 8. An increased number of free WLAGMI domains results in increased maximal po-
tentiation by 17-estradiol. The fit Rmax 1 is plotted against the number of free WLAGMI
domains predicted to be in the assembled receptor. The data were fit with two simple equa-
tions. The first is a linear increase (Rmax  1)  1  sM, where Rmax is the fit maximal
potentiation, s is the constant of proportionality, andM is the number of freeWLAGMI domains.
The second is a geometric increase (Rmax 1) r
M, where r is the relative increase in Rmax
conferred by adding one WLAGMI domain. The lines show the predicted dependence (dashed
linear, solidgeometric) and thedashed lines show1SEof the fits. The fit values are s1.6
0.1 (best fit 1 SE of parameter estimate) and r 1.62 0.02. The geometric fit was better
than the linear fit ( p 0.02, F test). Points showmean SE for data shown in Table 2. Note
that the symbol is sometimes larger than the error bar, and that the two data points at two free
WLAGMI overlap. The symbols match those in Figure 7.
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(N  11) for three tryptophans, and 7.7  2.7 (N  4) for five
tryptophans, although the regression coefficient (1.2  1.3; fit
value estimated SE of parameter) is not significantly different
from 0 ( p 0.39).
We tested a subset of additional constructs in which the critical
tryptophan was mutated. These were LLAAC and /LLAAC.
These constructs allowed us to test the effect of increasing numbers
of critical tryptophans in the absence of an untethered AGMI se-
quence, again holding the number of subunits with 2 N termini
constant at 2.Themeanpotentiation increased steadilywith increas-
ing numbers of tryptophans: /LLAAC&LLAAC (zero trypto-
phans: 1.16  0.03, five oocytes); /LLAAC&WLAAC (one:
1.20 0.09, four);/WLAAC&LLAAC (two: 1.56 0.15, four);
/WLAAC&WLAAC (three: 1.76  0.05, four). Linear regres-
sion of potentiation on the number of critical tryptophans for this
subset gives a regression coefficient of 0.22  0.04, which differs
from zero ( p 0.04).
Overall, the most significant observation is that removal of
potentiation by 17-estradiol does not remove potentiation by
17-vinylestradiol, indicating that the transduction mechanism
is retained.
Discussion
The goal of this study was to identify the critical portions of the
nicotinic 4 and 2 subunits required for potentiation by 17-
estradiol.We extended previous studies that had determined that
the C-terminal tail of the 4 subunit is necessary (Paradiso et al.,
2001; Curtis et al., 2002). Our starting hypothesis was that poten-
tiationwould be subunit specific and likelywould require that the
specific sequence be present on a subunit in a particular position
(e.g., on an 4 subunit involved in forming an agonist-binding
site). To our surprise, this hypothesis is incorrect in both respects.
The results indicate that the WLAGMI domain can be placed at
the C terminus of either the 4 or 2 subunit to subserve poten-
tiation. In addition, the subunit can participate in forming an
agonist-binding site or serve as the fifth, structural, subunit in the
receptor. As a corollary to these observations, the subunit with
the domain can be placed between 2 and 4 subunits or 4 and
2 subunits in the assembled receptor, so potentiation does not
appear to require a particular neighbor subunit.
Several observations support the idea that 17-estradiol inter-
acts with the receptor at the AGMI sequence. Because 17-
estradiol is a hydrophobic molecule, it can interact with the lipid
membrane. However, the enantiomer of 17-estradiol does not
potentiate (Paradiso et al., 2001). This enantioselectivity indi-
cates that potentiation requires interaction of steroid with an
optically active site, perhaps on the receptor. Potentiation is also
extremely sensitive to the structure of the WLAGMI domain—
mutations, insertions, or deletions can greatly reduce potentia-
tion. In addition, potentiation by 17-vinylestradiol is reduced
but not removed bymutation of AGMI (Paradiso et al., 2001; this
study). To remove potentiation by 17-vinylestradiol, it is nec-
essary to mutate both the AGMI sequence and the neighboring
tryptophan. This observation indicates that the AGMI sequence
is not required for transduction, in that 17-vinylestradiol still is
capable of potentiation. Furthermore, the finding that comple-
mentary changes in steroid and receptor structures affect poten-
tiation supports the idea that the D ring of the steroid associates
with the C-terminal WLAGMI tail to underlie potentiation. Fi-
nally, the present observations indicate that moving this defined
domain from one subunit to another can transfer potentiation.
Overall, these data support the conclusion that the C-terminal
domain is involved in molecular recognition (binding) rather
than the conversion of binding at a different site into functional
potentiation (transduction). However, previous work from our
laboratory (Paradiso et al., 2001) has shown that the molecular
structure of the A ring (the “other end” of the steroid molecule)
also is important for potentiation. The binding domain for the A
ring has not been localized, although the present data suggest that
it must be either to a sequence that is found in both the4 and2
subunits, or possibly lies in the membrane. Accordingly, it seems
most appropriate to call the C-terminal sequence a binding ele-
ment or binding domain.
It is surprising that potentiation can be transferred between
subunits simply by moving the WLAGMI sequence. Previous
studies of potentiating drugs show more specificity in sites. Sev-
eral potentiators interact with receptors in this gene family at
subunit interfaces in the extracellular region. The classic example
is benzodiazepine potentiation of GABAA receptor function (Si-
gel and Buhr, 1997), but potentiation of nicotinic 34* recep-
tors by morantel (Seo et al., 2009) or 4322 receptors by Zn
2
ions (Moroni et al., 2008) also requires specific residues in the
two subunits forming an interface. For more hydrophobic com-
pounds, etomidate appears to interact with transmembrane re-
gions of two subunits in the GABAA receptor to potentiate (Li et
al., 2006), whereas potentiating neurosteroids are proposed to
interact with two transmembrane domains of a single GABAA
subunit (Hosie et al., 2006). This estradiol-binding element ap-
pears to be remarkably discrete and effective at transferring
potentiation.
There are additional parts of the subunit(s) that appear to
influence the amount of potentiation (Curtis et al., 2002). The
cytoplasmic loop of the 4 subunit may reduce the amount of
potentiation transferred. This effect might result from an action
of the loop on transduction of potentiation, as there have been
reports in receptors in this family that the cytoplasmic loop can
affect channel function (Bouzat et al., 1994; Wang et al., 2000;
Kuo et al., 2005; Hales et al., 2006) or modulation (Swope et al.,
1999; Yevenes et al., 2008). In contrast, the TM4 helix of the 4
subunit appears to increase potentiation. As will be discussed
below, the action of 17-estradiol to potentiate responses may
result froman effect on the transmembrane helices to stabilize the
open-channel state of the receptor. Accordingly, the structure of
the TM4 region may influence the transduction mechanism. Al-
ternatively, it might be that the A ring of the steroid interacts with
some of the residues in the TM4 region. Additional experiments
will be required to elucidate the bases for these effects.
The mechanism by which potentiation is produced is not
known. Single-channel studies have shown that there is no in-
crease in the single-channel conductance (Curtis et al., 2002).
However, the probability of being open is increased, perhaps be-
cause of an increase in the duration of openings [Curtis et al.
(2002), their Fig. 4]. The increased probability of being open is
reminiscent of the effects ofmutations of the conserved leucine at
the ninth residue in the secondmembrane-spanning region. Nu-
merous studies have reported that mutation of TM2 L9 to more
hydrophilic residues increases the open probability of nicotinic
and related receptors (Revah et al., 1991; Labarca et al., 1995;
Chang et al., 1996). The increase is produced by amutation in any
of the five subunits in the receptor, and the overall effect increases
with number of mutated subunits (Labarca et al., 1995; Chang et
al., 1996;Moroni et al., 2006). These observations indicate that all
five subunits contribute to a conformational change before the
channel becomes permeable for ions and that the L9mutation in
any subunit therefore can shift the overall gating equilibrium.
Perhaps the interactionwith estradiol produces a conformational
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change in the transmembrane regions of that subunit that results
in a similar stabilization of the open state. The observation that
the extent of potentiation (efficacy) increases with increased
numbers of untethered WLAGMI regions is consistent with this
suggestion. The data suggest that each untethered WLAGMI in-
creases the maximal potentiation by 1.6-fold. The idea of an
independent action of 17-estradiol on any subunit that carries
an available WLAGMI sequence accounts well for the essential
features of our observations.
Drugs that enhance the response of synaptic receptors, with-
out directly interacting with the agonist-binding site, are of in-
creasing interest as therapeutic agents that do not produce a
response directly but enhance endogenous signaling. A number
of drugs that enhance GABAA receptor activity are in clinical use
as tranquilizers, sedatives, or hypnotics, first represented by the
benzodiazepines (Rudolph and Mo¨hler, 2004). More recently,
potentiators of the nicotinic 7 receptor have received attention
as possible agents to enhance cognition and memory (Lightfoot
et al., 2008). The nicotinic 4 subunit is quite prevalent in the
mammalian brain; the receptor comprising4 and2 subunits is
the most common heteromeric receptor and the 4 subunit also
participates in forming a variety of receptors of more complex
stoichiometry (Gotti et al., 2007). These receptors have their ma-
jor physiological effects by modulating the release of other neu-
rotransmitters, rather than directly mediating postsynaptic
responses in the brain (Dani and Bertrand, 2007). In particular, a
role for 4-containing receptors in control of dopamine release
has been proposed (Exley and Cragg, 2008), providing a possible
link to the reward pathway. The actions of endogenous com-
pounds, particularly steroids, are more difficult to define com-
pared with the effects of exogenously added drugs. There are two
principal difficulties in demonstrating a physiological role for
estradiol potentiation specifically of 4-containing nicotinic re-
ceptors. The first is that the concentration of 17-estradiol re-
quired for potentiation is high (1 M), much higher than the
levels in the brain (1 nM) (Mukai et al., 2006), although local
synthesis clearly occurs (Mukai et al., 2006; Cornil and Charlier,
2010) and could result in higher local levels. The second is that
17-estradiol has a multiplicity of effects in the nervous system,
both in sculpting development (cf. Gillies and McArthur, 2010)
and in more rapid changes in function (cf. Mukai et al., 2006;
Cornil and Charlier, 2010; Gillies and McArthur, 2010).
Overall, these observations indicate that the interaction be-
tween 17-estradiol and the nicotinic 42 receptor is mostly
determined by the discrete, C-terminal tail of a subunit. The
ability to transfer potentiation between subunits and the relation-
ship between numbers of WLAGMI domains and efficacy of po-
tentiation suggest that the effect of 17-estradiol is mediated by
actions on single subunits and that the overall consequences for
gating occur because of the summation of independent energetic
contributions to overall gating of this receptor.
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